Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells

Nature Communications
Hsin-Kai LiaoJuan Carlos Izpisua Belmonte

Abstract

To combat hostile viruses, bacteria and archaea have evolved a unique antiviral defense system composed of clustered regularly interspaced short palindromic repeats (CRISPRs), together with CRISPR-associated genes (Cas). The CRISPR/Cas9 system develops an adaptive immune resistance to foreign plasmids and viruses by creating site-specific DNA double-stranded breaks (DSBs). Here we adapt the CRISPR/Cas9 system to human cells for intracellular defense against foreign DNA and viruses. Using HIV-1 infection as a model, our results demonstrate that the CRISPR/Cas9 system disrupts latently integrated viral genome and provides long-term adaptive defense against new viral infection, expression and replication in human cells. We show that engineered human-induced pluripotent stem cells stably expressing HIV-targeted CRISPR/Cas9 can be efficiently differentiated into HIV reservoir cell types and maintain their resistance to HIV-1 challenge. These results unveil the potential of the CRISPR/Cas9 system as a new therapeutic strategy against viral infections.

References

Jun 4, 2002·Nature Medicine·Carl D NovinaPhillip A Sharp
Jun 28, 2002·Nature·Jean-Marc JacqueMario Stevenson
Nov 22, 2002·DNA and Cell Biology·Guocheng HeDavid M Margolis
Mar 15, 2003·The New England Journal of Medicine·Jacob P LalezariUNKNOWN TORO 1 Study Group
Jun 30, 2007·Science·Indrani SarkarFrank Buchholz
Jan 11, 2008·AIDS Research and Human Retroviruses·Milka A RodriguezPhalguni Gupta
Sep 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Keiichiro SuzukiKohnosuke Mitani
Mar 6, 2009·Retrovirology·Marylène MougelJean-Luc Darlix
Mar 7, 2009·Science·Douglas D RichmanRoger J Pomerantz
Mar 12, 2009·Current Gene Therapy·Reza Nazari, Sadhna Joshi
Mar 21, 2009·Nature Protocols·Robert H KutnerJakob Reiser
Dec 3, 2009·The New England Journal of Medicine·Paul E SaxUNKNOWN AIDS Clinical Trials Group Study A5202 Team
Jan 9, 2010·Science·Philippe Horvath, Rodolphe Barrangou
May 10, 2011·Nature Reviews. Microbiology·Kira S MakarovaEugene V Koonin
Feb 18, 2012·Nature·Blake WiedenheftJennifer A Doudna
Feb 23, 2012·Current Topics in Medicinal Chemistry·Mahmud Tareq Hassan KhanRoberto Gambari
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Giedrius GasiunasVirginijus Siksnys
Oct 19, 2012·Nature·Guang-Hui LiuJuan Carlos Izpisua Belmonte
Jan 5, 2013·Science·Le CongFeng Zhang
Jan 5, 2013·Science·Prashant MaliGeorge M Church
Jul 23, 2013·Nature Biotechnology·Patrick D HsuFeng Zhang
Aug 27, 2013·Scientific Reports·Hirotaka EbinaYoshio Koyanagi
Sep 24, 2013·Nature Reviews. Microbiology·Ursula Hofer
Dec 18, 2013·Science·Ophir ShalemFeng Zhang
Mar 7, 2014·The New England Journal of Medicine·Pablo TebasCarl H June
Apr 25, 2014·Viruses·Amit KumarGeorges Herbein
Jul 23, 2014·Proceedings of the National Academy of Sciences of the United States of America·Wenhui HuKamel Khalili
Aug 20, 2014·Molecular Therapy. Nucleic Acids·Su-Ru LinPei-Jer Chen
Sep 30, 2014·Trends in Molecular Medicine·Mohamed Abou-El-EneinChristian K Schneider
Oct 14, 2014·Cell·Luke A GilbertJonathan S Weissman

❮ Previous
Next ❯

Citations

Jan 23, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gang WangAtze T Das
Jan 19, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haiyan JiHuanzhang Zhu
Oct 27, 2015·International Journal of Molecular Sciences·Kentaro IshidaAkitsu Hotta
Apr 14, 2015·Expert Opinion on Biological Therapy·Sheena SaaymanMarc S Weinberg
Mar 1, 2016·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Yue MeiXing-Da Ju
Feb 8, 2016·Trends in Microbiology·Aryn A PriceDavid S Weiss
Jan 1, 2016·Antiviral Research·Harshana S De Silva FeelixgeKeith R Jerome
Oct 17, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Nataša Savić, Gerald Schwank
Nov 14, 2015·Annual Review of Pharmacology and Toxicology·Matthew Porteus
Nov 27, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Prajit LimsirichaiDavid V Schaffer
Jun 4, 2015·Cell Cycle·Hsin-Kai LiaoJuan Carlos Izpisua Belmonte
Nov 22, 2015·BMC Medicine·Chao LiuHui Zhang
Jul 3, 2015·Evolutionary Applications·Britt Koskella
Jun 20, 2015·Trends in Biotechnology·Mohamed Abou-El-EneinPetra Reinke
Apr 20, 2016·The Journal of Antimicrobial Chemotherapy·Pavitra RoychoudhuryJoshua T Schiffer
May 7, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Martyn K WhiteKamel Khalili
May 18, 2016·Biochemical and Biophysical Research Communications·Chuan LiJian-Hua Wang
May 28, 2016·Retrovirology·Chen LiangBen Berkhout
Sep 12, 2015·PloS One·Hassen S WolleboKamel Khalili
Jun 28, 2016·Briefings in Functional Genomics·Raul Torres-Ruiz, Sandra Rodriguez-Perales
Jun 10, 2016·Microbiology and Immunology·Shuhei UedaYoshio Koyanagi
Jun 18, 2016·The Journal of Eukaryotic Microbiology·Noelia LanderRoberto Docampo
Sep 9, 2016·Nature Biotechnology·Rodolphe Barrangou, Jennifer A Doudna
Sep 13, 2016·International Journal of Molecular Sciences·Francisco MartinKarim Benabdellah
Sep 14, 2016·Virus Research·Yan-Dong TangXue-Hui Cai
Oct 14, 2016·Blood Cells, Molecules & Diseases·Xiaotang Hu
Oct 11, 2016·Current Opinion in Virology·Frank Buchholz, Joachim Hauber
Nov 12, 2016·Gene·Vijai SinghPawan Kumar Dhar
Nov 18, 2016·AIDS Patient Care and STDs·Keith R Jerome
Nov 20, 2016·Cellular Microbiology·M DoerflingerM J Herold
Jul 1, 2016·PLoS Pathogens·Ferdy R van DiemenRobert Jan Lebbink
Dec 13, 2016·Genes·Vera KlemmChantelle Ahlenstiel
Aug 17, 2016·Scientific Reports·Rafal KaminskiKamel Khalili
Nov 15, 2016·Scientific Reports·Yi-Ying ChouTom Kirchhausen
May 31, 2017·ACS Synthetic Biology·Michael PinedaSamira Kiani
Feb 9, 2017·Scientific Reports·Robert Jan LebbinkMonique Nijhuis
May 2, 2017·Journal of Cellular Biochemistry·Martyn K WhiteKamel Khalili
Jan 18, 2018·Viruses·Shuliang ChenDeyin Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Virology & CRISPR

This feed focuses on the virology of CRISPR and its use in developing CRISPR-Cas systems. Discover the latest research here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.